Ashwin Gollerkeri
Corporate Officer/Principal chez KYMERA THERAPEUTICS, INC.
Profil
Ashwin Gollerkeri is currently the Senior Vice President & Head-Development at Kymera Therapeutics, Inc. Previously, he held the same position at Array BioPharma, Inc. He completed his undergraduate degree at Northwestern University and his doctorate at Kansas City University of Medicine & Biosciences.
Postes actifs de Ashwin Gollerkeri
| Sociétés | Poste | Début |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Corporate Officer/Principal | 03/02/2021 |
Anciens postes connus de Ashwin Gollerkeri
| Sociétés | Poste | Fin |
|---|---|---|
| ARRAY TECHNOLOGIES, INC. | Corporate Officer/Principal | - |
Formation de Ashwin Gollerkeri
| Kansas City University of Medicine & Biosciences | Doctorate Degree |
| Northwestern University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KYMERA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |